0001214659-22-010328.txt : 20220817 0001214659-22-010328.hdr.sgml : 20220817 20220817153502 ACCESSION NUMBER: 0001214659-22-010328 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220816 FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MORRIS TIMOTHY E CENTRAL INDEX KEY: 0001191286 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38599 FILM NUMBER: 221173723 MAIL ADDRESS: STREET 1: ACELRX PHARMACEUTICALS, INC. STREET 2: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc. CENTRAL INDEX KEY: 0001398733 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208623253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-941-1900 MAIL ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: MonoSol Rx, Inc. DATE OF NAME CHANGE: 20070507 4 1 marketforms-56912.xml PRIMARY DOCUMENT X0306 4 2022-08-16 0001398733 Aquestive Therapeutics, Inc. AQST 0001191286 MORRIS TIMOTHY E C/O AQUESTIVE THERAPEUTICS, INC 30 TECHNOLOGY DRIVE WARREN NJ 07059 true false false false Non-Qualified Stock Option (right to buy) 1.50 2022-08-16 4 A false 28500 0 A 2032-08-16 Common Stock 28500 28500 D Granted under the Company's 2018 Equity Incentive Plan, which meets the requirements of Rule 16b-3. The options will vest in three annual installments with 1/3% on the 1st installment, 1/3% on the 2nd installment and 1/3% on the 3rd installment. /s/ Lori Braender, as Attorney-In-Fact 2022-08-17 EX-24 2 poa.htm POA DOCUMENT

      POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes
and appoints each of Lori J. Braender, A. Ernest Toth, Jr., Valerie Borchevsky
and Ellen S.
Knarr, signing singly, the undersigned's true and lawful attorney-in-fact to:
(i) execute for and on
behalf of the undersigned, in the undersigned's capacity as a director of
Aquestive Therapeutics,
Inc. (the "Company"), a Form ID, including updates thereto, and Forms 3, 4, and
5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934 and the rules
thereunder; (ii) do and
perform any and all acts for and on behalf of the undersigned which may be
necessary or
desirable to complete and execute any such Form ID, including updates thereto,
or Form 3, 4, or
5 and timely file such form with the United States Securities and Exchange
Commission and any
stock exchange or similar authority; and (iii) take any other action of any type
whatsoever in
connection with the foregoing which, in the opinion of such attorney-in-fact,
may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the
documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power
of Attorney shall be in such form and shall contain such terms and conditions as
such attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all
intents and purposes as the undersigned might or could do if personally present,
with full power
of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney
and the rights and powers herein granted. The undersigned acknowledges that the
foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section
16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned
is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and
transactions in securities issued by the Company, unless earlier revoked by the
undersigned in a
signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 12 day of August, 2022.
Timothy E. Morris